Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 5/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | DRD1 | P21728 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15348353 | 0.93 | HTR7 (0.48) | HPGDHTR1ADRD2HTR2AHTR7 | |
| SCHEMBL12469282 | 0.82 | DRD2 (0.56) | HTR1ADRD2HTR2AADRA1AHTR7 | |
| SCHEMBL12468808 | 0.76 | DRD2 (0.58) | HTR1ADRD2HTR2AADRA1AHTR7 | |
| SCHEMBL12469195 | 0.75 | KCNH2 (0.54) | HTR1ADRD1ADRA1AHTR7SLC6A4 | |
| SCHEMBL12469049 | 0.75 | ALDH1A1 (0.48) | HPGDNPC1RAB9A | |
| SCHEMBL12468893 | 0.73 | SIGMAR1 (0.53) | HTR1ADRD2ADRA1AHTR7NPC1 | |
| SCHEMBL12468880 | 0.71 | DRD2 (0.46) | HTR1ADRD2HTR2ADRD1ADRA1D | |
| SCHEMBL12468939 | 0.71 | DRD2 (0.52) | DRD2HTR2AHTR2C | |
| SCHEMBL7592384 | 0.71 | HTR1A (0.60) | HTR1ADRD2HTR2ADRD1HTR2C | |
| SCHEMBL9287528 | 0.70 | HTR1A (0.55) | HPGDHTR1ADRD2HTR2ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | EPIOMED THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012051601-A2 | HETEROARYLTHIO COMPOUNDS | EPIOMED THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | NLN, HTT, ABAT | HPGD 2294/4885HTR1A 288/4885DRD2 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.